Clinically, Dr. Floberg focuses on the treatment of genitourinary cancers. As a radiation oncologist, he collaborates with urologists, medical oncologists, radiologists, pathologists and other specialists to provide patients with the best care possible.
Dr. Cosper’s main interest is in Human Papilloma Virus (HPV) induced cancers, such as cervical and head and neck cancer. Specifically, she is interested in how the virus induces different types of chromosomal instability (CIN) and how this affects radiation sensitivity, which may offer some insight into radiation sensitivity or resistance within HPV+ cancers.
The Morris Lab is focused on using preclinical and translational research approaches to study the mechanisms whereby radiation may impact the anti-tumor response to immunotherapies. Their primary objective is to determine whether and how radiation may optimally be employed to simultaneously modulate the tumor immune microenvironment and to increase the susceptibility of tumor cells to immune response. They seek to test these approaches in early phase clinical studies where they may be further refined with the ultimate aim of improving survival and achieving cures in patients with metastatic cancers.
Dr. Cooley is a clinical associate professor in the Department of Human Oncology (DHO). The DHO is one of the few centers in the region offering both low-dose-rate and high-dose-rate prostate brachytherapy. Two decades ago, prostate brachytherapy showed superior PSA control rates. With further advances in dosing, fractionation and MRI-based planning, results are even better.